دورية أكاديمية
أعرض في EDS

Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study.

التفاصيل البيبلوغرافية
العنوان: Cost-Effectiveness of Cerebrolysin after Ischemic Stroke: Secondary Analysis of the CARS Study.
المؤلفون: Strilciuc S; Department of Neuroscience, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.; RoNeuro Institute for Neurological Research and Diagnostic, 400364 Cluj-Napoca, Romania.; Department of Public Health, Faculty of Political, Administrative and Communication Sciences, Babes-Bolyai University, 400084 Cluj-Napoca, Romania., Radu C; Yale School of Public Health, Yale University, New Haven, CT 06520, USA., Grad DA; RoNeuro Institute for Neurological Research and Diagnostic, 400364 Cluj-Napoca, Romania.; Department of Public Health, Faculty of Political, Administrative and Communication Sciences, Babes-Bolyai University, 400084 Cluj-Napoca, Romania., Stan AD; Department of Neuroscience, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.; RoNeuro Institute for Neurological Research and Diagnostic, 400364 Cluj-Napoca, Romania., Vladescu C; National Institute for Management of Health Services, 021254 București, Romania.; Faculty of Medicine, Titu Maiorescu University, 031595 București, Romania., Buzoianu AD; Department of Clinical Pharmacology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania., Muresanu D; Department of Neuroscience, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.; RoNeuro Institute for Neurological Research and Diagnostic, 400364 Cluj-Napoca, Romania.
المصدر: Healthcare (Basel, Switzerland) [Healthcare (Basel)] 2023 May 21; Vol. 11 (10). Date of Electronic Publication: 2023 May 21.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101666525 Publication Model: Electronic Cited Medium: Print ISSN: 2227-9032 (Print) Linking ISSN: 22279032 NLM ISO Abbreviation: Healthcare (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2013]-
مستخلص: The cost-effectiveness of Cerebrolysin as an add-on therapy for moderate-severe acute ischemic stroke is a topic that remains understudied. This study aims to address this gap by performing a comprehensive cost-utility analysis using both deterministic and probabilistic methods from a payer perspective and within the Romanian inpatient care setting. Quality-adjusted life years (QALYs) were calculated using partial individual patient data from the 2016 Cerebrolysin and Recovery After Stroke (CARS) trial, utilizing three different health state valuation models. Cost data was extracted from actual acute care costs reported by Romanian public hospitals for reimbursement purposes for patients included in the CARS study. Incremental cost-effectiveness ratios were calculated for each treatment arm for the duration of the clinical trial. Deterministic analysis based on sample mean values indicates Cerebrolysin would be cost-effective at a threshold between roughly 18.8 and 29.9 thousand EUR, depending on valuation techniques. Probabilistic sensitivity analysis results indicate an 80% chance probability of cost-effectiveness of Cerebrolysin as an add-on therapy for acute ischemic stroke, considering a willingness-to-pay threshold of 50,000 EUR in a 90-day timeframe after stroke. Further economic evaluations of Cerebrolysin are needed to strengthen these findings, covering a timeframe of at least 12 months after the acute incident, which would account for treatment effects spanning beyond the first 90 days after ischemic stroke. These should be conducted to determine its cost-effectiveness under various care settings and patient pathways. Most importantly, modelling techniques are needed to answer important questions such as the estimates of population gain in QALYs after acute administration of Cerebrolysin and the potential offsetting of direct medical costs as a result of administering the intervention.
References: Lancet. 2009 Jan 24;373(9660):349-51. (PMID: 19167573)
Neurol Sci. 2020 May;41(5):1171-1181. (PMID: 31897941)
Value Health Reg Issues. 2016 Sep;10:41-47. (PMID: 27881276)
Crit Care Med. 2020 Nov;48(11):1654-1663. (PMID: 32947473)
Neurology. 2021 Jun 8;96(23):e2824-e2838. (PMID: 33766997)
J Mark Access Health Policy. 2020 Feb 15;8(1):1717030. (PMID: 32158523)
Value Health. 2007 Sep-Oct;10(5):336-47. (PMID: 17888098)
Neurol Sci. 2020 Feb;41(2):281-293. (PMID: 31494820)
Front Public Health. 2020 Dec 04;8:605919. (PMID: 33344405)
Eur Heart J Qual Care Clin Outcomes. 2019 Jul 1;5(3):195-201. (PMID: 31050714)
Health Policy. 2022 May;126(5):382-390. (PMID: 34246501)
Stroke. 2020 Jul;51(7):1996-2001. (PMID: 32432997)
Stroke. 2016 Jun;47(6):e98-e169. (PMID: 27145936)
J Med Life. 2021 Sep-Oct;14(5):700-709. (PMID: 35027974)
J Neurointerv Surg. 2022 Jul;14(7):642-649. (PMID: 35387860)
Neurol Sci. 2018 Apr;39(4):629-640. (PMID: 29248999)
Pharmacoeconomics. 2018 May;36(5):509-522. (PMID: 29427072)
Eur Stroke J. 2023 Jan;8(1 Suppl):44-51. (PMID: 36793744)
Eur J Neurol. 2021 Sep;28(9):2831-2845. (PMID: 34152062)
Pharmaceuticals (Basel). 2021 Dec 13;14(12):. (PMID: 34959697)
J Neural Transm (Vienna). 2008 May;115(5):683-92. (PMID: 18273537)
Stroke. 2016 Jan;47(1):151-9. (PMID: 26564102)
Health Syst Transit. 2016 Aug;18(4):1-170. (PMID: 27603897)
J Med Life. 2021 Sep-Oct;14(5):606-619. (PMID: 35027963)
Stroke. 2022 Jun;53(6):2078-2081. (PMID: 35514281)
Stroke. 2013 Mar;44(3):828-40. (PMID: 23362084)
BMC Health Serv Res. 2020 May 19;20(1):435. (PMID: 32429985)
Health Policy. 2022 May;126(5):362-372. (PMID: 34311982)
Lancet Neurol. 2020 Apr;19(4):348-360. (PMID: 32004440)
Stroke Res Treat. 2021 Jul 29;2021:8653396. (PMID: 34336181)
Int J Stroke. 2017 Jul;12(5):444-450. (PMID: 28697708)
Eur Stroke J. 2018 Dec;3(4):309-336. (PMID: 31236480)
Can J Neurol Sci. 2011 Jul;38(4):612-20. (PMID: 21672701)
Stroke. 2020 Aug;51(8):2418-2427. (PMID: 32646325)
Cochrane Database Syst Rev. 2020 Apr 23;4:CD000197. (PMID: 32324916)
Lancet Neurol. 2021 Oct;20(10):795-820. (PMID: 34487721)
Int J Stroke. 2020 Oct;15(7):755-762. (PMID: 32525468)
Lancet. 2022 Sep 24;400(10357):974-975. (PMID: 36063822)
Brain Sci. 2021 May 24;11(6):. (PMID: 34073732)
Lancet. 2018 Nov 10;392(10159):2052-2090. (PMID: 30340847)
فهرسة مساهمة: Keywords: cerebrolysin; cost-effectiveness; stroke
تواريخ الأحداث: Date Created: 20230527 Latest Revision: 20230530
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10218347
DOI: 10.3390/healthcare11101497
PMID: 37239783
قاعدة البيانات: MEDLINE
الوصف
تدمد:2227-9032
DOI:10.3390/healthcare11101497